Mr. Elms joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, he was a Principal in the Life Sciences Investment Banking Group of Chase H&Q (formerly Hambrecht & Quist, “H&Q”). During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.
Mr. Elms currently serves as chairman of the board of Adma Biologics and Elevation Oncology; a board member of Marker Therapeutics, Medical Knowledge Group, Treeline Biosciences, and Zosano Pharma; and a board observer of Verona Pharma. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Advion BioSciences (acquired by Bohui Innovation Technology), Ambit Biosciences (acquired by Daiichi-Sankyo), Archimica Cooperatief (acquired by Euticals), Avera Pharmaceuticals, Bioenvision (acquired by Genzyme), CeNeRx BioPharma, Cidara Therapeutics, EarLens, LENSAR, Loxo Oncology (acquired by Eli Lilly), MAP Pharmaceuticals (acquired by Allergan), NextWave Pharmaceuticals (acquired by Pfizer), Novazyme Pharmaceuticals (acquired by Genzyme), Oculex Pharmaceuticals (acquired by Allergan), Pernix Therapeutics, Scerene Healthcare and TRIA Beauty. He also serves on the INVO Board at Northwestern University.
Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.